New drug cocktail shows promise for Hard-to-Treat breast cancer before surgery

NCT ID NCT07618923

Not yet recruiting Disease control Sponsor: Tang-Du Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial is testing a three-drug combination given before surgery for people with intermediate-to-high risk HR-positive, HER2-low breast cancer. Participants first take dalpiciclib (a pill) plus an aromatase inhibitor (another pill) for about 4 months, followed by infusions of SHR-A1811 for another 3 months. The goal is to see how well the treatment shrinks tumors before surgery, with 20 participants enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dalpiciclib, aromatase inhibitor (anastrozole, letrozole, or exemestane), and SHR-A1811
What this could lead to: If successful, this combination could offer a more effective way to shrink tumors before surgery for people with this type of breast cancer, potentially leading to better long-term outcomes.
What could go wrong: This is a small, early-phase study with only 20 participants, so results may not apply to everyone. The drugs can cause side effects, and the treatment may not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER HR POSITIVE/HER2 LOW BREAST CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.